Definitive Contract 75F40123C00196
Award Date
9/21/23
Potential Completion Date
9/20/25
Potential Value
$876K
Federal Agency
Food and Drug Administration
Awardee
Virginia Commonwealth University
Ultimate Awardee
Not listed
PSC Category
B504 - Special Studies/Analysis- Chemical/Biological
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Richmond, VA 23298, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services, Food and Drug Administration awarded a firm-fixed price definitive contract to Virginia Commonwealth University (VCU) to evaluate relationships between in vitro nasal spray characterization test metrics for bioequivalence and nasal deposition in silico and in vitro. The contract has a potential value of $1,136,057.48 and a completion date of July 30, 2021. VCU, a public research university located in Richmond, Virginia, has a broad range of federal...
The Department of Health and Human Services Food and Drug Administration awarded Virginia Commonwealth University, doing business as V C U, a definitive contract valued at approximately $1.6 million to conduct an evaluation of current approaches used to establish bioequivalence of nasal sprays for local action in children. The contract is a firm fixed price award with performance taking place in Richmond, Virginia over a three-year period concluding in January 2024. No set aside designation or...
This $4,236,731 definitive contract was awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Virginia Commonwealth University (VCU) for preclinical medications discovery and abuse liability testing services. The contract supports NIDA's Addiction Treatment Discovery Program, under which VCU will evaluate potential pharmacotherapies for drug use disorders in rodents and primates, and conduct abuse liability testing of new drugs using behavioral pharmacology models. This...
This is a $5,833,141.44 cost-reimbursable contract awarded by the National Institute on Drug Abuse (NIDA), part of the Department of Health and Human Services, to Virginia Commonwealth University (VCU) for medication discovery research using rat models of drug relapse. The contract has a period of performance from July 10, 2019 to July 9, 2024, with the initial award covering the first year. This contract was awarded under a competitive solicitation that was open to small businesses only, but no...
This federal contract award is for $126,725.04 and was issued by the Department of Justice Drug Enforcement Administration to the prime contractor, Virginia Commonwealth University (VCU), located in West Springfield, VA. The contract is for study reports and results from the scientific investigation of the in vivo analgesic effects. This is a firm fixed price purchase order with a completion date of November 30, 2019. There is no set-aside designation mentioned for this award. VCU, doing...
The U.S. Food and Drug Administration (FDA) awarded a $1,155,442.55 Cost Plus Fixed Fee contract to Cubrc, Inc. to conduct research and development on the "Immunogenicity Risk of Peptide Drug Generics and Their Impurities: In Silico and In Vitro Assessment and Validation Methods." The contract, which has a period of performance ending September 27, 2022, was issued under the FDA's Broad Agency Announcement (BAA) solicitation for advanced research and development to support regulatory...
This is a firm fixed-price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Virginia Commonwealth University (VCU) for sample collection services. The contract has a total ceiling value of $59,337.43 and a period of performance ending on March 31, 2022. VCU is a public research university that provides a wide range of services to the federal government, including...
The Food and Drug Administration (FDA) awarded a $1,046,568.62 firm-fixed price delivery order to Integrated Behavioral Health, Inc., a for-profit subchapter S corporation, to study the prevalence, experiences, knowledge, and perceptions of falsified and unapproved pharmaceuticals among individuals being assessed for or entering substance use disorder treatment. This delivery order is part of a larger $10 million indefinite delivery contract the FDA has with Integrated Behavioral Health to...
This is a federal contract award to Virginia Commonwealth University (VCU) for biomedical research and services. The contract has a total ceiling value of $247,803.04 and was awarded on April 15, 1999 with a completion date of April 30, 2011. The contract is a definitive contract with a cost no fee pricing type. The contract was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which is a civilian agency under the Department of Health and Human Services....
This federal contract award from the Food and Drug Administration (FDA) to Battelle Memorial Institute, a nonprofit research and development organization, is for investigating the effects of nicotine pouch flavors on abuse liability in smokeless tobacco users. The $1,923,145.00 firm fixed-price delivery order has a period of performance ending on May 30, 2026. The award does not have a set-aside designation. Battelle has subcontracted with Montrose Environmental Group, Inc., an environmental...